Communication objective associated: Demonstrate Dysport® benefits and applicability across patient types
Dysport® could provide sustained benefits in daily life, specifically in everyday tasks that involve carrying, reaching, grasping and releasing
Dysport® helps enable patients to walk faster, giving them the confidence to maintain their independence
Real-world studies show these improvements happen consistently, cycle after cycle, in routine practice.
Key supportive study :
Key material:
Digital material for follow up:
Communication objective associated: Demonstrate efficiency and clinic benefits of using Dysport®
Dysport® is proven to deliver sustained symptom control in phase 3 clinical trials
Dysport® demonstrated longer-lasting symptom control vs other BoNT-As in routine clinical practice in upper limb spasticity
Longer intervals between injections mean fewer appointments and lower overall treatment costs.
Main key supportive study :
Key material:
Digital material for follow up:
Communication objective associated: Demonstrate efficiency and clinic benefits of using Dysport®
Dysport® contains more active neurotoxin within the licensed maximum dose than any other avaible BoNT-A
62% of patients responded to Dysport® when the upper limb was their primary treatment target; 83% for lower limb.
Recommended doses for upper / lower limb muscles
Dysport® has a dose-response effect
Main key supportive study :
Key material:
Digital material for follow up:
Communication objective associated: Demonstrate efficiency and clinic benefits of using Dysport®
Main key supportive study :
Key material:
Communication objective associated: Emphasize accessibility of HCP support to simplify patient and clinic management
Key material
Digital material for follow up
